NCT06940349 (COPS-01) is a Phase 1, PHASE2 clinical trial of Palbociclib in Solid Tumors Refractory to Standard Therapy, sponsored by Rabin Medical Center.

Who is sponsoring NCT06940349?

NCT06940349 is sponsored by Rabin Medical Center.

What drugs are being tested in NCT06940349?

Interventions in NCT06940349: Palbociclib, Sunitinib.

What condition does NCT06940349 study?

NCT06940349 studies Solid Tumors Refractory to Standard Therapy.

Is NCT06940349 still recruiting?

NCT06940349 is currently recruiting now. Last updated 23 April 2025.

Last reviewed 2025-04-23 · How we verify

NCT06940349: COPS-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

Recruiting now Phase 1, PHASE2 Last updated 23 April 2025

What this trial tests

Phase 1, PHASE2 trial testing Palbociclib in Solid Tumors Refractory to Standard Therapy in 100 participants. Currently enrolling.

Timeline

21 October 2021

Primary endpoint
1 January 2026

1 January 2028

Quick facts

Lead sponsor	Rabin Medical Center
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	21 October 2021
Primary completion	1 January 2026
Estimated completion	1 January 2028
Sites	1 location across Israel

Drugs / interventions tested

Palbociclib (Palbociclib) — full drug profile →
Sunitinib (sunitinib) — full drug profile →

Conditions studied

Solid Tumors Refractory to Standard Therapy — all drugs for Solid Tumors Refractory to Standard Therapy →

Sponsor

Rabin Medical Center

Who can join

18 and older, any sex, with Solid Tumors Refractory to Standard Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors. The main questions it aims to answer are: * Is the drugs combination safe for the participants? * Is the drug combination effective in all solid malignancies? It is a single arm study, phase 1b/2, dose escalation and expansion, to determine the safety, tolerability and initial efficacy of this combination. Participants will: * Take the drugs combination every day for 5 executive days, and 2 days of, in a 28 days cycle, for up to a year. * Visit the clinic once every 2 weeks for checkups and tests

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Palbociclib

Trials testing the same drug.

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06997029 — A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors · Phase 1 · recruiting

Other recruiting trials for Solid Tumors Refractory to Standard Therapy

Currently open trials in the same condition.

NCT06911333 — AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06883539 — A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. · Phase 1 · recruiting

Other Rabin Medical Center trials

Trials by the same sponsor.

NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06940349 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
Last refreshed: 23 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06940349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing